RxDoctor Payments Data

Ashley Berry, NP

Adult Health · Oregon, OHNPI 1972891299

Payments from drug & device makers

$2,339in general payments, 2019–2025

Across 128 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$507
  • AbbVie$378
  • E.r. Squibb & Sons, L.L.C.$192
  • Pfizer$182
  • Lilly USA, LLC$145
  • Novartis$118
  • plus $818 from 20 others

What the payments were for

  • Food & beverage$2,32799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,339 in reported general payments places this provider in the 80th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$9,363
Medicare patients
33
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin11$14,794
OzempicSemaglutide11$13,595
Sucralfate29$3,041
Enoxaparin Sodium19$2,002
Pantoprazole Sodium140$1,313
Atorvastatin Calcium75$823
Omeprazole58$689
Rosuvastatin Calcium24$645
Famotidine42$492
Gabapentin17$401
Levothyroxine Sodium28$348
ClopidogrelClopidogrel Bisulfate25$250
Ondansetron Hcl53$210
Losartan Potassium20$200
Metformin Hcl ErMetformin Hcl45$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$49$14,79411 claims
Novo NordiskOzempic$507$13,59511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,184 adult health providers in Ohio.

Other adult health in Oregon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →